New drug combo aims to keep early breast cancer from returning
NCT ID NCT07581834
First seen May 17, 2026 · Last updated Jun 24, 2026 · Updated 8 times
Summary
This study is testing whether adding the drug dalpiciclib to standard hormone therapy can help prevent breast cancer from coming back in women with early-stage HR+/HER2- breast cancer. About 2,000 women will receive either a higher dose for 2 years or a lower dose for 3 years, along with hormone therapy. Researchers will track how long women live without their cancer returning and monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Cancer Hosptial
RECRUITINGFuzhou, Fujian, 350001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
West China Hospital of Sichuan University
NOT_YET_RECRUITINGChengdu, Sichuan, 618099, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dalpiciclib (a CDK4/6 inhibitor) combined with endocrine therapy (letrozole, anastrozole, or exemestane)
What this could lead to
If successful, this could offer a new adjuvant treatment option that lowers the risk of breast cancer returning in women with early-stage HR+/HER2- disease.
What could go wrong
This is a phase 2 trial, so results are still preliminary. The two different doses and durations are being compared, and side effects like low blood cell counts may occur. It is not yet proven to be better than current standard care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.